LexBlog IP

DECEMBER 13, 2023

The post Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation appeared first on Big Molecule Watch.

Litigation 52

Litigation Settlement Licensing Marketing 52

LexBlog IP

MARCH 6, 2024

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. The agreement allows Biocon to launch in the United States in February 2025, pending FDA approval. 10,961,307, which claims methods of treating ulcerative colitis with ustekinumab. Amgen secured a U.S.

Marketing 52

Marketing Marketing Settlement Licensing 52

LexBlog IP

MARCH 6, 2024

announced it has signed a settlement agreement with Bayer Inc. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. On March 4, Biocon Biologics Ltd. and Regeneron Pharmaceuticals, Inc.

Marketing 52

Marketing Marketing Settlement Litigation 52

JD Supra Law

AUGUST 3, 2023

Notably, since our last update, Janssen and Amgen reached a settlement allowing for the launch of Amgen’s biosimilar to Stelara no later than January 1, 2025. Since the enactment of the Biologics Price Competition and Innovation Act (BPCIA), 41 biosimilars have been approved, 22 of which have launched. By: Morgan Lewis

Settlement 52

Settlement Litigation Patent 52

SpicyIP

MARCH 15, 2024

Since parties could not arrive at a settlement, ID initiated patent infringement proceedings against the defendants in UK, Germany and India. If the trial spills over to 2025, the defendants will have to bear the cost for that as well. The parties commenced joint negotiations in 2021.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

Bio Law Blog

JUNE 21, 2020

On May 28, Alexion and Amgen entered into a confidential settlement agreement to terminate the IPRs. Pursuant to the terms of the settlement agreement, effective March 1, 2025 (or earlier in certain circumstances), Alexion grants to Amgen a nonexclusive, royalty-free license under U.S. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

LexBlog IP

NOVEMBER 5, 2023

According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.” .” (CMS’s position on this has been challenged in pending litigation.)

Marketing 40

Marketing Marketing Government Litigation 40

The IPKat

FEBRUARY 29, 2024

It is likely therefore that it will stand to be determined by a High Court judge some time in 2025. It is unlikely that the Mitchell and Redding estates will be prepared to settle for anything less than a very substantial payout – something that Sony does not, at this stage – appear to be minded to agree.

Copyright 109

Copyright Reporting Contracts Settlement 109

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. With the enactment of the MSME Act,2006; an effective mechanism has emerged, enhancing the MSME claim settlement procedure and striving to make it more accessible.

Settlement 52

Settlement Intellectual Property Registration Designs 52

LexBlog IP

JANUARY 25, 2024

According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.” .” (CMS’s position on this has been challenged in pending litigation.)

Marketing 52

Marketing Marketing Licensing Litigation 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

No earlier than July 31, 2023 per settlement. No earlier than November 20, 2023 per settlement. . No earlier than June 30, 2023 per settlement. No earlier than September 30, 2023 per settlement. No earlier than July 1, 2023 per settlement. No earlier than January 31, 2023 per settlement. January 2021.

Settlement 52

Settlement Litigation Marketing Marketing 52

LexBlog IP

FEBRUARY 18, 2024

The remaining proposals are entitled: “ PTAB Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement.” In 2025 we will likely have a new Director, and perhaps a new Fintiv memo.

Settlement 52

Settlement Publishing Patent Intellectual Property 52

Herbert Smith Freehills

SEPTEMBER 10, 2021

Under this model , SA’s emissions would peak between 2020 and 2025 as reflected in South Africa's National Climate Change Response Policy and then plateau for approximately a decade before declining in absolute terms. Through the strategy Angola intends to reach a seventy per cent renewable capacity by 2025.

Government 64

Government Reporting Publishing Settlement 64